214 related articles for article (PubMed ID: 25252915)
1. SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines.
Srivastava AK; Dinc G; Sharma RK; Yolcu ES; Zhao H; Shirwan H
Cancer Res; 2014 Nov; 74(22):6441-51. PubMed ID: 25252915
[TBL] [Abstract][Full Text] [Related]
2. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.
Sharma RK; Elpek KG; Yolcu ES; Schabowsky RH; Zhao H; Bandura-Morgan L; Shirwan H
Cancer Res; 2009 May; 69(10):4319-26. PubMed ID: 19435920
[TBL] [Abstract][Full Text] [Related]
3. Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner.
Srivastava AK; Sharma RK; Yolcu ES; Ulker V; MacLeod K; Dinc G; Shirwan H
PLoS One; 2012; 7(11):e48463. PubMed ID: 23144888
[TBL] [Abstract][Full Text] [Related]
4. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.
Sharma RK; Srivastava AK; Yolcu ES; MacLeod KJ; Schabowsky RH; Madireddi S; Shirwan H
Vaccine; 2010 Aug; 28(36):5794-802. PubMed ID: 20603135
[TBL] [Abstract][Full Text] [Related]
5. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines.
Sharma RK; Schabowsky RH; Srivastava AK; Elpek KG; Madireddi S; Zhao H; Zhong Z; Miller RW; Macleod KJ; Yolcu ES; Shirwan H
Cancer Res; 2010 May; 70(10):3945-54. PubMed ID: 20406989
[TBL] [Abstract][Full Text] [Related]
6. Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant.
Dinc G; Pennington JM; Yolcu ES; Lawrenz MB; Shirwan H
Vaccine; 2014 Sep; 32(39):5035-40. PubMed ID: 25045812
[TBL] [Abstract][Full Text] [Related]
7. A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4
Barsoumian HB; Batra L; Shrestha P; Bowen WS; Zhao H; Egilmez NK; Gomez-Gutierrez JG; Yolcu ES; Shirwan H
Cancer Res; 2019 Feb; 79(4):783-794. PubMed ID: 30770367
[TBL] [Abstract][Full Text] [Related]
8. SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.
Sharma RK; Yolcu ES; Shirwan H
Expert Rev Vaccines; 2014 Mar; 13(3):387-98. PubMed ID: 24521311
[TBL] [Abstract][Full Text] [Related]
9. An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression.
Ragonnaud E; Andersson AM; Pedersen AE; Laursen H; Holst PJ
Vaccine; 2016 Apr; 34(18):2147-56. PubMed ID: 27004934
[TBL] [Abstract][Full Text] [Related]
10. CD4+ T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models.
Sharma RK; Yolcu ES; Srivastava AK; Shirwan H
PLoS One; 2013; 8(9):e73145. PubMed ID: 24066030
[TBL] [Abstract][Full Text] [Related]
11. SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ.
Madireddi S; Schabowsky RH; Srivastava AK; Sharma RK; Yolcu ES; Shirwan H
PLoS One; 2012; 7(8):e42459. PubMed ID: 22870329
[TBL] [Abstract][Full Text] [Related]
12. Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine.
Gableh F; Saeidi M; Hemati S; Hamdi K; Soleimanjahi H; Gorji A; Ghaemi A
J Biomed Sci; 2016 Jan; 23():16. PubMed ID: 26811064
[TBL] [Abstract][Full Text] [Related]
13. Long-term antigen-specific immune response by an oncolytic adenovirus encoding SP-SA-E7-4-1BBL in HPV-16 cancer model.
Martinez-Perez AG; Garza-Morales R; Loera-Arias MJ; Villa-Cedillo SA; Garcia-Garcia A; Rodriguez-Rocha H; Flores-Maldonado OE; Valdes J; Perez-Trujillo JJ; Saucedo-Cardenas O
Mol Biol Rep; 2024 Mar; 51(1):408. PubMed ID: 38460043
[TBL] [Abstract][Full Text] [Related]
14. CD4 T-cells transduced with CD80 and 4-1BBL mRNA induce long-term CD8 T-cell responses resulting in potent antitumor effects.
Park HM; Sohn HJ; Kim YJ; Cho HI; Kim TG
Vaccine; 2014 Dec; 32(51):6919-6926. PubMed ID: 25444817
[TBL] [Abstract][Full Text] [Related]
15. Development of a potent melanoma vaccine capable of stimulating CD8(+) T-cells independently of dendritic cells in a mouse model.
Powell KL; Stephens AS; Ralph SJ
Cancer Immunol Immunother; 2015 Jul; 64(7):861-72. PubMed ID: 25893808
[TBL] [Abstract][Full Text] [Related]
16. 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.
Kudo-Saito C; Hodge JW; Kwak H; Kim-Schulze S; Schlom J; Kaufman HL
Vaccine; 2006 Jun; 24(23):4975-86. PubMed ID: 16621183
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling.
Elpek KG; Yolcu ES; Franke DD; Lacelle C; Schabowsky RH; Shirwan H
J Immunol; 2007 Dec; 179(11):7295-304. PubMed ID: 18025172
[TBL] [Abstract][Full Text] [Related]
18. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
19. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
[TBL] [Abstract][Full Text] [Related]
20. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function.
Wen T; Bukczynski J; Watts TH
J Immunol; 2002 May; 168(10):4897-906. PubMed ID: 11994439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
